dual LRRK-2/JNK inhibitors (Scripps Research Institute)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Namedual LRRK-2/JNK inhibitors (Scripps Research Institute)
Drug Alias Namedual leucine-rich repeat kinase 2/c-jun-N-terminal kinase inhibitor (Scripps Research Institute)SR-9444
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Actionc-Jun N-terminal kinase inhibitorsLeucine-rich repeat serine/threonine-protein kinase 2 inhibitors
TargetsLeucine-rich repeat serine/threonine-protein kinase 2c-Jun N-terminal kinase
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesThe Scripps Research Institute Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesThe Scripps Research Institute Inc
Active IndicationsN/A
Inactive IndicationsParkinson Disease

Other Information

ATC CodeN/A
Related LinksN/A